


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:


1. (Currently amended) A compound represented by the formula



wherein Ring A represents an optionally substituted pyridine ring, X represents an electron-attracting group, Y represents an optionally substituted divalent C₁₋₆ chained hydrocarbon group selected from the group consisting of a C₁₋₆ alkylene group, a C₂₋₆ alkenylene group, and a C₂₋₆ alkynylene group-CH=CH- or -(CH₂)₂, R¹ represents (1) a C₅₋₇ cycloalkyl group optionally fused with a benzene ring, (2) a C₇₋₁₉ aralkyl group, (3) a 5- or 6-membered heterocyclic ring-C₁₋₄ alkyl group or (4) a C₆₋₁₄ aryloxy-C₁₋₄ alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C₁₋₄ alkyl group, a mono-, di- or tri-halogeno-C₁₋₄ alkyl group and a C₁₋₄ alkoxy group, an optionally substituted hydrocarbon group selected from the group consisting of aliphatic hydrocarbon group, alicyclic hydrocarbon group, alicyclic-aliphatic hydrocarbon group and aromatic hydrocarbon group, and R² and R³ each independently represent a hydrogen atom, an optionally substituted hydrocarbon group selected from the group consisting of aliphatic hydrocarbon group, alicyclic hydrocarbon group, alicyclic-aliphatic hydrocarbon group and aromatic hydrocarbon group, a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄

~~aryl and C₇₋₁₉ aralkyl or an optionally substituted heterocyclic group selected from the group consisting of a 5 to 14 membered (mono to tri-cyclic) heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom tetrahydropyranyl, pyranyl and pyridyl, or R² and R³ may form an optionally substituted ring together with an adjacent nitrogen atom, or a salt thereof.~~

2. (Original) The compound according to claim 1 which is a compound represented by the formula



wherein Ring A'' represents a pyridine ring which may have 1 to 3 substituents selected from a C₁₋₄ alkyl group and a mono-, di- or tri-halogeno-C₁₋₄ alkyl group and other symbols are as defined in claim 1, or a salt thereof.

3. (Original) The compound according to claim 1, wherein X is a nitrile group.
4. (Canceled).
5. (Canceled).

6. **(Currently amended)** The compound according to claim 1, wherein one of R² and R³ is a hydrogen atom or a C₁₋₄ alkyl group, and the other is a ~~5- or 6-membered heterocyclic group,~~ a C₆₋₁₄ aryl group, a C₇₋₁₉ aralkyl group, a C₃₋₁₀ cycloalkyl group, a tetrahydropyranyl, pyranyl and pyridyl~~5- or 6-membered heterocyclic ring~~ C₁₋₄ alkyl group or C₁₋₆ alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C₁₋₄ alkyl group, a mono-, di- or tri-halogeno-C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a C₁₋₄ alkoxy-carbonyl group, a cyano group, a C₁₋₄ alkyl-carbonylamino group and a hydroxy group; ~~or R² and R³, together with an adjacent nitrogen atom, form a 5- or 6-membered nitrogen-containing heterocyclic ring optionally containing 1 to 3 hetero-atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to carbon atoms and one nitrogen atom, in which the nitrogen-containing heterocyclic ring may have 1 to 4 substituents selected from a halogen atom, a C₁₋₄ alkyl group, a mono-, di- or tri-halogeno-C₁₋₄ alkyl group, a C₁₋₄ alkoxy group and a C₁₋₄ alkoxy-carbonyl group.~~

7. **(Original)** (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethoxyphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethylphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-methyl-N-phenylprop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3-methylphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-

pyrrolo[2,3-b]pyridin-2-yl}-N-(4-hydroxy-3-methoxyphenyl)prop-2-enamide, or salts thereof.

8. **(Canceled).**
9. **(Previously presented)** A medicine comprising the compound according to claim 1.
10. **(Original)** The medicine according to claim 9 which is a vanilloid receptor agonist.
11. **(Original)** The vanilloid receptor agonist according to claim 10 which is for local administration.
12. **(Currently amended)** The vanilloid receptor agonist according to claim 10 which is an agent for ~~preventing and/or~~ treating overactive bladder.
13. **(Original)** The vanilloid receptor agonist according to claim 10 which is an analgesic.
14. **(Currently amended)** A method of treating overactive bladder, comprising administering to a mammal in need an effective amount of the compound according to claim 1 ~~or a prodrug thereof.~~

15. (Previously presented) An analgesic method comprising administering to a mammal in need an effective amount of the compound according to claim 1.

16. (Canceled).

17. (Canceled).